55 | Regulatory Arbitrage: Managing Disruption During Platform Shifts • NYC TLC

54 | Distribution Shifts: Business Model Disruption Destroys Moats • Seinfeld / Veep

52 | Value Chain Ascension: Repositioning Low-Margin Manufacturing • Alene Candles

26 | Strategic Vulnerability: Speed & Convenience vs. Scale • Blockbuster

66 | Data Interoperability: Extracting Value from Siloed Datasets • Embark

51 | Resolving Scale Bottlenecks Through Structural Incentive Alignment • Danaher

Open Source Biotech: Building Symbiosis in the Biotech Ecosystem

42 | Strategic Divestment: Shedding Legacy Assets to Rebuild Growth • Revvity

36 | Owning Data Control Points: Moat Construction in Tech • Thermo Fisher Scientific

34 | R&D Capital Efficiency as an Operational Imperative • Sanofi

32 | Organizational Endurance: Deciphering Internal Signal vs. Noise • Philips

30 | Platform Compatibility vs. Bespoke Engineering • Mammoth Biosciences

29 | Early Path Dynamics: Initial Conditions & Long-Term Health • Brigham & Women's

23 | Bio-Infrastructure: Refactoring Legacy Biological Code • Dr. George Church

21 | Platform Standardization: Speed-to-Market in Clinical R&D • MGH

18 | Hardware to Ecosystem Pivots: Problem Definition Over Features • Siemens

17 | Portfolio Theory in Deep Tech: Managing Non-Linear R&D • Dr. Robert Langer

12 | Continuous Data Pipelines vs. Point-in-Time Diagnostics • Beacon Biosignals

11 | Augmenting Human Capital: Precision as a Competitive Advantage • PathAI

09 | Timing & Sequencing: Why First-Movers Lose to Precise Scalers • Caris Life Sciences

07 | Managing Uncertainty at Scale: Lessons from Big Science • Human Genome Project